GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shockwave Medical Inc (NAS:SWAV) » Definitions » ROE %

Shockwave Medical (Shockwave Medical) ROE % : 27.91% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Shockwave Medical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Shockwave Medical's annualized net income for the quarter that ended in Dec. 2023 was $177.2 Mil. Shockwave Medical's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $635.0 Mil. Therefore, Shockwave Medical's annualized ROE % for the quarter that ended in Dec. 2023 was 27.91%.

The historical rank and industry rank for Shockwave Medical's ROE % or its related term are showing as below:

SWAV' s ROE % Range Over the Past 10 Years
Min: -145.89   Med: -3.91   Max: 57.36
Current: 24.8

During the past 7 years, Shockwave Medical's highest ROE % was 57.36%. The lowest was -145.89%. And the median was -3.91%.

SWAV's ROE % is ranked better than
94.8% of 808 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs SWAV: 24.80

Shockwave Medical ROE % Historical Data

The historical data trend for Shockwave Medical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shockwave Medical ROE % Chart

Shockwave Medical Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -145.89 -31.41 -3.91 57.36 24.96

Shockwave Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 129.98 28.93 19.44 22.98 27.91

Competitive Comparison of Shockwave Medical's ROE %

For the Medical Devices subindustry, Shockwave Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shockwave Medical's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shockwave Medical's ROE % distribution charts can be found below:

* The bar in red indicates where Shockwave Medical's ROE % falls into.



Shockwave Medical ROE % Calculation

Shockwave Medical's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=147.278/( (511.316+668.677)/ 2 )
=147.278/589.9965
=24.96 %

Shockwave Medical's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=177.22/( (601.245+668.677)/ 2 )
=177.22/634.961
=27.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Shockwave Medical  (NAS:SWAV) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=177.22/634.961
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(177.22 / 811.916)*(811.916 / 1520.261)*(1520.261 / 634.961)
=Net Margin %*Asset Turnover*Equity Multiplier
=21.83 %*0.5341*2.3943
=ROA %*Equity Multiplier
=11.66 %*2.3943
=27.91 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=177.22/634.961
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (177.22 / 221.84) * (221.84 / 173.128) * (173.128 / 811.916) * (811.916 / 1520.261) * (1520.261 / 634.961)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7989 * 1.2814 * 21.32 % * 0.5341 * 2.3943
=27.91 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Shockwave Medical ROE % Related Terms

Thank you for viewing the detailed overview of Shockwave Medical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shockwave Medical (Shockwave Medical) Business Description

Traded in Other Exchanges
Address
5403 Betsy Ross Drive, Santa Clara, CA, USA, 95054
ShockWave Medical Inc is a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Its intravascular lithotripsy technology is used in the treatment of calcified plaque. Geographically, the company generates its revenue from the United States, Europe and other countries.
Executives
Douglas Evan Godshall director, officer: President & CEO SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Frank T Watkins director 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Isaac Zacharias officer: Chief Commercial Officer 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Dan Puckett officer: CFO & Secretary 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Trinh Phung officer: VP, Finance C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Laura Francis director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Sara Toyloy director C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Kevin J. Ballinger director C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Antoine Papiernik director, 10 percent owner 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Sofinnova Capital Vii Fcpr 10 percent owner C/O SOFINNOVA PARTNERS, 18 RUE DU 4 SEPTEMBRE, 75002 PARIS I0 00000
Cahill Colin director 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Frederic H Moll director C/O INTUITIVE SURGICAL INC, 950 KIFER ROAD, SUNNYVALE CA 94086
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Larkin C Raymond Jr director C/O MALLINCKRODT INC, 7733 FORSYTH BLVD, ST LOUIS MO 63105